- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Psoriatic arthritis Crohn disease Chronic plaque psoriasis Ulcerative colitis Fistulising Crohn disease
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 579KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 108KB)
Ustekinumab – March 2024
Ustekinumab: Injection 45 mg in 0.5 mL single use pre filled syringe, Injection 45 mg in 0.5 mL single use pre filled pen, Injection 90 mg in 1 mL single use pre filled syringe, Injection 90 mg in 1 mL single use pre filled pen; Stelara®
Last updated
30 May 2025
